Senores Pharmaceuticals Ltd Fundamentals
Compare peers 
SHAREHOLDING PATTERN
Promoter Holdings45.00%45.00%0.00%
Promoter Pledge0.00%0.00%0.00%
Swapnil Jatin Shah7.72%
Ashokbhai Vijaysinh Barot7.44%
Remus Pharmaceuticals Limited7.08%
Renosen Pharmaceuticals Private Limited5.87%
Anar Swapnil Shah4.98%
Senores Pharmaceuticals Limited was originally incorporated as ‘Senores Pharmaceuticals Private Limited’ under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registr Read more 
IndustryPharmaceuticals & Drugs
SectorHealthcare
Top subsidiariesRatnatris Pharmaceuticals Pvt Ltd.Senores Pharmaceuticals IncHavix Group Inc
MANAGEMENT
ChairmanSanjay Shaileshbhai Majmudar
Non Independent & Non Executive DirectorAshokkumar Vijaysinh Barot
Managing DirectorSwapnil Jatinbhai Shah
Non Independent & Non Executive DirectorJitendra Babulal Sanghvi
Whole Time Director & Chief Operating OfficerChetan Bipinchandra Shah
Company Secretary & Compliance OfficerVinay Kumar Mishra
Non Independent & Non Executive DirectorArpit Deepakkumar Shah
Non Executive Independent DirectorNaresh Bansilal Shah
Non Executive Independent DirectorManjula Devi Shroff
Non Executive Independent DirectorUdayan Dileep Choksi
Non Independent & Non Executive DirectorHemanshu Nitinchandra Pandya
Non Executive Independent DirectorKalpit Rajesh Gandhi
Whole Time Director & Chief Financial OfficerDeval Rajnikant Shah
ChairmanSanjay Shaileshbhai Majmudar
Non Independent & Non Executive DirectorAshokkumar Vijaysinh Barot
Managing DirectorSwapnil Jatinbhai Shah
Non Independent & Non Executive DirectorJitendra Babulal Sanghvi
Whole Time Director & Chief Operating OfficerChetan Bipinchandra Shah
Company Secretary & Compliance OfficerVinay Kumar Mishra
Non Independent & Non Executive DirectorArpit Deepakkumar Shah
Non Executive Independent DirectorNaresh Bansilal Shah
Non Executive Independent DirectorManjula Devi Shroff
Non Executive Independent DirectorUdayan Dileep Choksi
Non Independent & Non Executive DirectorHemanshu Nitinchandra Pandya
Non Executive Independent DirectorKalpit Rajesh Gandhi
Whole Time Director & Chief Financial OfficerDeval Rajnikant Shah
ChairmanSanjay Shaileshbhai Majmudar
Non Independent & Non Executive DirectorAshokkumar Vijaysinh Barot
Managing DirectorSwapnil Jatinbhai Shah
Non Independent & Non Executive DirectorJitendra Babulal Sanghvi
Whole Time Director & Chief Operating OfficerChetan Bipinchandra Shah
Company Secretary & Compliance OfficerVinay Kumar Mishra
Non Independent & Non Executive DirectorArpit Deepakkumar Shah
Non Executive Independent DirectorNaresh Bansilal Shah
Non Executive Independent DirectorManjula Devi Shroff
Non Executive Independent DirectorUdayan Dileep Choksi
Non Independent & Non Executive DirectorHemanshu Nitinchandra Pandya
Non Executive Independent DirectorKalpit Rajesh Gandhi
Whole Time Director & Chief Financial OfficerDeval Rajnikant Shah
ChairmanSanjay Shaileshbhai Majmudar
Non Independent & Non Executive DirectorAshokkumar Vijaysinh Barot
Managing DirectorSwapnil Jatinbhai Shah
Non Independent & Non Executive DirectorJitendra Babulal Sanghvi
Whole Time Director & Chief Operating OfficerChetan Bipinchandra Shah
Company Secretary & Compliance OfficerVinay Kumar Mishra
Non Independent & Non Executive DirectorArpit Deepakkumar Shah
Non Executive Independent DirectorNaresh Bansilal Shah
Non Executive Independent DirectorManjula Devi Shroff
Non Executive Independent DirectorUdayan Dileep Choksi
Non Independent & Non Executive DirectorHemanshu Nitinchandra Pandya
Non Executive Independent DirectorKalpit Rajesh Gandhi
Whole Time Director & Chief Financial OfficerDeval Rajnikant Shah
Address1101 To 1103, 11th Floor, South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road ,Ahmedabad ,Gujarat-380054.
Telephone079-29999857
MORE DETAILSNSE Code28888
NSE SymbolSENORES
SeriesEQ
ISININE0RB801010
Senores Pharmaceuticals Limited was originally incorporated as ‘Senores Pharmaceuticals Private Limited’ under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. The name of the Company was thereafter changed to ‘Senores Pharmaceuticals Limited’ upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing it as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, it strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.It leverages its RD capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Its focus on quality and its ability to identify specialty and complex molecules has resulted in a pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through its partnerships in the Regulated Markets of US, Canada and United Kingdom with foreign and Indian pharmaceutical companies.Products of the companyMarketed ProductsANDA ProductsAcetaminophen Butalbital and Acetaminophen Butalbital CaffeineChlorzoxazoneDiclofenac potassiumKetorolacMexiletine HydrochlorideSourced ProductsAwards, accreditations and recognitions2022: Its subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘general’ section.2022: Its Subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘B-lactum’ section.2023: Its Subsidiary, RPPL, received the WHO-GMP certificate from the FDA in the ‘manufacturer’ category.2023: Its Subsidiary, RPPL, received the GLP certificate from the FDA.2024: The Atlanta Facility of its Subsidiary, Havix, was audited and approved by the USFDA.History and milestones2021: Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021: Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.2022: Started the domestic business with a launch of the critical care injectables.2023: Acquired majority stake in Havix., making it a Subsidiary of the company2023: Consolidated its presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a subsidiary of the company.2024: Launched first CMO product in the US with Jubilant Cadista.
